drugset / Trial / NCT06745271
A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine the routes, rates of elimination, mass balance of total radioactivity and metabolite profiles following a single oral dose of \[14C\]-tebapivat. To characterize the PK of tebapivat and \[13C2,15N3\]-tebapivat and determine the absolute bioavailability following single oral dose of \[14C\]-tebapivat relative to single intravenous microdose of \[13C2,15N3\]-tebapivat to healthy male participants.
Timeline
- Start
- 2024-12-20
- Primary completion
- 2025-02-21
- Completion
- 2025-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tebapivat | Small molecule | 0.1 mg | Oral |
| Subject | Tebapivat | Small molecule | 10 mg | Oral |
Indications
No indication recorded.